보고서 요약(국문)

개요
전 세계 기관지확장증 치료제 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
기관지확장증은 기관지 벽이 염증과 감염으로 인해 두꺼워지는 만성 질환입니다. 기관지확장증 환자는 주기적으로 호흡 곤란이 악화되는 증상을 경험합니다.
기관지확장증의 증상으로는 만성 기침, 호흡 곤란, 객혈, 흉통 등이 있습니다. 종양이나 양성 종양과 같은 기도 폐쇄 또한 기관지확장증을 유발할 수 있습니다. 기관지확장증 치료에 일반적으로 사용되는 약물로는 항생제, 거담제, 점액용해제 등이 있습니다.
시장 동향
기관지확장증 유병률 증가
기관지확장증 유병률의 증가는 시장 성장의 주요 동인으로 작용합니다. 기관지확장증은 만성 폐쇄성 폐질환이 있는 경우 흔히 발생하며, 병리학적으로 영구적인 기관지 확장과 심한 기관지 염증을 특징으로 합니다.
예를 들어, 2022년 미국 국립보건원(NIH) 보고서에 따르면 중국 성인의 기관지확장증 유병률은 10만 명당 75.48명(62.26, 88.69)에서 174.45명(137.02, 211.88)으로 2.31배 증가했습니다.
또한, 2022년 12월 호주 왕립 일반의사협회(RACP) 보고서에 따르면 호주 중부 지역 어린이의 기관지확장증 유병률은 10만 명당 1470명으로 추정됩니다.

또한, 폐 질환 발병률 증가, 고령 인구 증가, 임상 시험 증가와 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.

승인된 약물 부족
기관지확장증에 대한 승인된 약물 부족, 엄격한 규제 정책, 연구 개발에 소요되는 높은 비용, 기관지확장증의 진단 부족, 대체 치료 선호도 등은 예측 기간 동안 기관지확장증 치료 시장의 성장을 저해하는 요인입니다.
세분화 분석
전 세계 기관지확장증 치료제 시장은 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
항생제 부문은 시장 점유율의 약 52.2%를 차지했습니다.
항생제는 기관지확장증에 대한 항생제 임상 시험 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 2023년까지 기관지확장증 치료를 위한 항생제 임상 시험은 총 314건이 수행되었습니다.

예를 들어, clinicalTrials.gov에 따르면, 2023년 9월 7일 벨파스트 보건사회복지국(Belfast Health and Social Care Trust)은 퀸즈대학교(Queen's University)와 협력하여 기관지확장증 환자를 대상으로 고장성 식염수와 카르보시스테인의 임상시험을 시작했습니다. 현재 3상 임상시험이 진행 중이며, 예상 완료일은 2024년 9월입니다.
또한, 2023년 9월 21일 인스메드(Insmed Incorporated)는 낭포성 섬유증이 없는 기관지확장증 환자를 대상으로 브렌소카팁(Brensocatib)의 효능, 안전성 및 내약성에 대한 임상시험을 실시했습니다. 이 임상시험 역시 현재 3상 임상시험이 진행 중이며, 예상 완료일은 2024년 3월입니다.
지역별 분석
북미는 전 세계 기관지확장증 치료제 시장에서 상당한 점유율을 차지할 것으로 예상됩니다.
전 세계 기관지확장증 치료제 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다.

북미는 기관지확장증 감염률 증가 및 신약 승인 등의 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 2022년 미국 폐협회(American Lung Association) 보고서에 따르면 기관지확장증 발병 위험은 나이가 들수록 증가하며, 미국에서는 35만~50만 명이 기관지확장증을 앓고 있습니다. 기관지확장증은 남성보다 여성에게서 더 흔하게 발생합니다.
또한, 2022년 4월 Zambon은 비낭포성 섬유증 기관지확장증(NCFB) 성인 환자의 폐 악화 발생률 감소를 위한 분무 용액용 콜리스티메테이트 나트륨 분말에 대해 미국 FDA 혁신 치료제 지정을 받았습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 기관지확장증 치료제 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 임상시험 진행에 차질이 생겼고, 많은 임상시험 기관에서 환자 안전을 최우선으로 고려하여 등록을 일시적으로 중단하거나 프로토콜을 수정했습니다. 이로 인해 임상시험 완료 및 신약 출시가 지연되었습니다. 따라서 기관지확장증 치료제 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Zambon S.p.A., Pfizer Inc., Merck KGaA, Soigner Pharma Pvt Ltd, Teva Pharmaceuticals, LGM Pharma LLC, Texas Pharmaceuticals Pvt. Ltd., Orion Life Science, Cepham Life Sciences Inc., AdvaCare Pharma 등이 있습니다.
주요 개발 사항
• 2023년 9월, Inogen Inc.는 Physio-Assist SAS를 인수했습니다. Physio-Assist의 기술 기반 기도 청소 및 점액 관리 장치인 Simeox는 주로 기관지확장증 치료에 사용됩니다.

• 2022년 12월, 생명과학 자선단체인 LifeArc는 유럽 다기관 기관지확장증 감사 및 연구 협력(EMBARC)과 파트너십을 맺고 호흡기 질환인 기관지확장증 퇴치를 위한 노력을 시작했습니다.
보고서 구매 이유:

• 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 전 세계 기관지확장증 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 전 세계 기관지확장증 치료제 시장의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

전 세계 기관지확장증 치료제 시장 보고서는 약 69개의 표, 67개의 그림, 그리고 185페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Bronchiectasis Drugs Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Bronchiectasis is a chronic condition where the walls of the bronchi are thickened from inflammation and infection. Individuals with bronchiectasis have periodic flare-ups of breathing difficulties called exacerbations.
Symptoms of bronchiectasis include chronic cough with shortness of breath, coughing up blood, and chest pain. The airway blockage like a growth or a noncancerous tumor can also lead to bronchiectasis. Common drugs used in the treatment of bronchiectasis include antibiotics, expectorants, and mucolytics
Market Dynamics
Increasing prevalence of bronchiectasis
The increasing prevalence of bronchiectasis acts as a significant driver for market growth. Bronchiectasis often occurs in the presence of chronic obstructive pulmonary disease and is characterized pathologically by permanent bronchial dilatation and severe bronchial inflammation.
For instance, according to a National Institute of Health report published in 2022, Chinese adults had a 2.31-fold increase in the prevalence of bronchiectasis, going from 75.48 (62.26, 88.69) per 100,000 to 174.45 (137.02, 211.88) per 100,000.
Additionally, according to the Royal Australian College of General Practitioners report published in December 2022, states that the estimated prevalence of bronchiectasis is 1470 per 100,000 in Central Australian children.
Furthermore, significant growth drivers such as the rising incidence of pulmonary diseases, the growing geriatric population, and increasing clinical trials, are expected to drive the market in the forecast period.
The lack of approved drugs
The lack of approved drugs for bronchiectasis, stringent regulatory policies, high costs involved in research and development under-diagnosis of bronchiectasis, and preference for substitute treatment options are some factors hampering the growth of the bronchiectasis treatment market over the forecast period.
Segment Analysis
The global bronchiectasis drugs market is segmented based on disease type, drug type, route of administration, distribution channel, and region.
The antibiotics segment accounted for approximately 52.2% of the market share
Antibiotics are expected to hold the largest market share over the period forecast owing to increasing clinical trials conducted for bronchiectasis with antibiotics. A total of 314 clinical trials were performed till 2023 for the treatment of bronchiectasis with antibiotics.
For instance, according to clinicalTrials.gov, on September 7, 2023, Belfast Health and Social Care Trust in collaboration with Queen's University started a clinical trial of Hypertonic Saline and Carbocisteine in Bronchiectasis. It is currently in phase 3 and the estimated study completion date is September 2024.
Additionally, on September 21, 2023, Insmed Incorporated conducted a clinical trial on the efficacy, safety, and tolerability of Brensocatib in participants with non-cystic fibrosis bronchiectasis. It is currently in phase 3 and the estimated study completion date is March 2024.
Geographical Analysis
North America is expected to hold a significant position in the global bronchiectasis drugs market share
The global bronchiectasis drugs market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of bronchiectasis infections and drug approvals, this trend is anticipated to continue throughout the forecast period.
For instance, according to the American Lung Association report published in 2022, The risk of developing bronchiectasis increases with age, and Bronchiectasis affects 350,000 to 500,000 people in the United States. The incidence of bronchiectasis is more common in women than in men.
Additionally, in April 2022, Zambon received a U.S FDA Breakthrough Therapy Designation for colistimethate sodium powder for nebulization solution for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB).
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global bronchiectasis drugs market. The pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new treatment drugs. Therefore, the bronchiectasis drugs market is expected to be moderately affected over the forecast period.
Competitive Landscape
The major global players in the market include Zambon S.p.A., Pfizer Inc., Merck KGaA, Soigner Pharma Pvt Ltd, Teva Pharmaceuticals, LGM Pharma LLC, Texas Pharmaceuticals Pvt. Ltd., Orion Life Science, Cepham Life Sciences Inc., AdvaCare Pharma among others.
Key Developments
• In September 2023, Inogen Inc. acquired Physio-Assist SAS. A technology-enabled airway clearance and mucus management device, Simeox from Physio-Assist, is primarily used to treat bronchiectasis.
• In December 2022, Life science charity LifeArc partnered with the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) to tackle the respiratory disease bronchiectasis.
Why Purchase the Report?
• To visualize the global bronchiectasis drugs market segmentation based on disease type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global bronchiectasis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global bronchiectasis drugs market report would provide approximately 69 tables, 67 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of bronchiectasis
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. The lack of approved drugs
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. CF Bronchiectasis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-CF Bronchiectasis
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Antibiotics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Erythromycin
8.2.4. Clarithromycin
8.2.5. Roxithromycin
8.2.6. Azithromycin
8.2.7. Amoxicillin
8.2.8. Others
8.3. Expectorants
8.3.1. Hypertonic Saline
8.3.2. Inhaled Mannitol
8.3.3. Others
8.4. Mucolytics
8.4.1. Bromhexine
8.4.2. N-Acetylcysteine
8.4.3. Erdosteine
8.4.4. Fudosteine
8.4.5. Others
8.5. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Inhalation
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Retail Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospital Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Zambon S.p.A.
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Pfizer Inc.
13.3. Merck KGaA
13.4. Soigner Pharma Pvt Ltd
13.5. Teva Pharmaceuticals
13.6. LGM Pharma LLC
13.7. Texas Pharmaceuticals Pvt. Ltd.
13.8. Orion Life Science
13.9. Cepham Life Sciences Inc.
13.10. AdvaCare Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Zambon S.p.A., 4. Key Developments, Pfizer Inc., Merck KGaA, Soigner Pharma Pvt Ltd, Teva Pharmaceuticals, LGM Pharma LLC, Texas Pharmaceuticals Pvt. Ltd., Orion Life Science, Cepham Life Sciences Inc., AdvaCare Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Bronchiectasis Drugs Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Bronchiectasis Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Bronchiectasis Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Bronchiectasis Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Bronchiectasis Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Bronchiectasis Drugs Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 8 Global Bronchiectasis Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 10 Global Bronchiectasis Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Bronchiectasis Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Bronchiectasis Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Bronchiectasis Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 17 North America Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 18 North America Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Bronchiectasis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 South America Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 23 South America Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Bronchiectasis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 27 Europe Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 28 Europe Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Bronchiectasis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Bronchiectasis Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Bronchiectasis Drugs Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Bronchiectasis Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Bronchiectasis Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Bronchiectasis Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Zambon S.p.A.: Overview

Table 41 Zambon S.p.A.: Product Portfolio

Table 42 Zambon S.p.A.: Key Developments

Table 43 Pfizer Inc.: Overview

Table 44 Pfizer Inc.: Product Portfolio

Table 45 Pfizer Inc.: Key Developments

Table 46 Merck KGaA: Overview

Table 47 Merck KGaA: Product Portfolio

Table 48 Merck KGaA: Key Developments

Table 49 Soigner Pharma Pvt Ltd: Overview

Table 50 Soigner Pharma Pvt Ltd: Product Portfolio

Table 51 Soigner Pharma Pvt Ltd: Key Developments

Table 52 Teva Pharmaceuticals: Overview

Table 53 Teva Pharmaceuticals: Product Portfolio

Table 54 Teva Pharmaceuticals: Key Developments

Table 55 LGM Pharma LLC: Overview

Table 56 LGM Pharma LLC: Product Portfolio

Table 57 LGM Pharma LLC: Key Developments

Table 58 Texas Pharmaceuticals Pvt. Ltd.: Overview

Table 59 Texas Pharmaceuticals Pvt. Ltd.: Product Portfolio

Table 60 Texas Pharmaceuticals Pvt. Ltd.: Key Developments

Table 61 Orion Life Science: Overview

Table 62 Orion Life Science: Product Portfolio

Table 63 Orion Life Science: Key Developments

Table 64 Cepham Life Sciences Inc.: Overview

Table 65 Cepham Life Sciences Inc.: Product Portfolio

Table 66 Cepham Life Sciences Inc.: Key Developments

Table 67 AdvaCare Pharma: Overview

Table 68 AdvaCare Pharma: Product Portfolio

Table 69 AdvaCare Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 3 Global Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 4 Global Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 6 Global Bronchiectasis Drugs Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Bronchiectasis Drugs Market Y-o-Y Growth, By Disease Type, 2022-2031 (%)

Figure 8 CF Bronchiectasis Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Non-CF Bronchiectasis Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Global Bronchiectasis Drugs Market Y-o-Y Growth, By Drug Type, 2022-2031 (%)

Figure 11 Antibiotics Drug Type in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Expectorants Drug Type in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 13 Mucolytics Drug Type in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 14 Others Drug Type in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Global Bronchiectasis Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 16 Oral Route of Administration in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Parenteral Route of Administration in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 18 Inhalation Route of Administration in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 19 Global Bronchiectasis Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 20 Retail Pharmacies Distribution Channel in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Hospital Pharmacies Distribution Channel in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 22 Online Pharmacies Distribution Channel in Global Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 23 Global Bronchiectasis Drugs Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 24 North America Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 Asia-Pacific Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 26 Europe Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 27 South America Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 28 Middle East and Africa Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 29 North America Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 30 North America Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 31 North America Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 32 North America Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 33 North America Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 34 North America Bronchiectasis Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 35 South America Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 36 South America Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 37 South America Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 38 South America Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 39 South America Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 40 South America Bronchiectasis Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 41 Europe Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 42 Europe Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 43 Europe Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 44 Europe Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 45 Europe Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 46 Europe Bronchiectasis Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 47 Asia-Pacific Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 48 Asia-Pacific Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 49 Asia-Pacific Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 50 Asia-Pacific Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 51 Asia-Pacific Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 52 Asia-Pacific Bronchiectasis Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 53 Middle East & Africa Bronchiectasis Drugs Market Value, 2022-2031 (US$ Million)

Figure 54 Middle East & Africa Bronchiectasis Drugs Market Share, By Disease Type, 2022 & 2031 (%)

Figure 55 Middle East & Africa Bronchiectasis Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 56 Middle East & Africa Bronchiectasis Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 57 Middle East & Africa Bronchiectasis Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 58 Zambon S.p.A.: Financials

Figure 59 Pfizer Inc.: Financials

Figure 60 Merck KGaA: Financials

Figure 61 Soigner Pharma Pvt Ltd: Financials

Figure 62 Teva Pharmaceuticals: Financials

Figure 63 LGM Pharma LLC: Financials

Figure 64 Texas Pharmaceuticals Pvt. Ltd.: Financials

Figure 65 Orion Life Science: Financials

Figure 66 Cepham Life Sciences Inc.: Financials

Figure 67 AdvaCare Pharma: Financials

세계 기관지확장증 치료제 시장 – 2023-2030

Global Bronchiectasis Drugs Market - 2023-2030